Cardinal is using its own cyclotron installations to produce Gozellix for distribution across a range of US locations.

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

BrainStorm has attempted to gain market approval for NurOwn without success but remains committed to developing the cell therapy.

The recommendation was based on results from the Phase III THOR trial, which compared Balversa to chemotherapy.

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

NEW YORK – Singapore's Experimental Drug Development Center (EDCC) will use Engine Biosciences' machine-learning platform to advance precision cancer therapies, according to a partnership announced ...

The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.

In a mouse model, a single dose of ATL-201 durably suppressed seizures and improved behavior through six months, according to the firm.

The approval was based on results from a Phase III trial showing that Opdivo-Yervoy improved outcomes against Opdivo alone and chemo alone.

The biotech firm closed an oversubscribed Series C funding round, proceeds from which it will use to advance ATSN-201 and its ...

NEW YORK – Adaptin Bio on Monday said it has completed a reverse merger with a subsidiary of Unite Acquisition 1 Corp to bring the company public and closed a private placement worth up to $7.7 ...